CTI BIOPHARMA CORP

Form 4 March 20, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

subject to Section 16. Form 4 or Form 5

orm 4 or
orm 5
ligations

obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person **
BIANCO LOUIS A

(Street)

2. Issuer Name **and** Ticker or Trading Symbol

Issuer LODILA DIMA. CORD (CTIC)

(Last) (First) (Middle) 3. Date of Earliest Transaction

3. Date of Earliest Transaction

3101 WESTERN AVE, SUITE 600 03/20/2015

(Month/Day/Year)

O3/20/2015

Director

X Officer (give title Other (specify below)

EVP, Finance & Administration
4. If Amendment, Date Original
6. Individual or Joint/Group Filing(Chec

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

5. Relationship of Reporting Person(s) to

(Check all applicable)

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

_X_Form filed by One Reporting Person ___ Form filed by More than One Reporting

Person

SEATTLE, WA 98121

(City)	(State)	(Zip) Tabl	le I - Non-E	Derivative	Securi	ities Acqu	ired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount		Price	(Instr. 3 and 4)		
Common Stock	03/20/2015		S(1)	10,000	D	\$ 1.92	1,075,152	D	
Common Stock	03/20/2015		S <u>(1)</u>	1,300	D	\$ 1.923	1,073,852	D	
Common Stock	03/20/2015		S(1)	15,900	D	\$ 1.93	1,057,952	D	
Common Stock	03/20/2015		S(1)	17,100	D	\$ 1.94	1,040,852	D	
Common Stock	03/20/2015		S <u>(1)</u>	5,100	D	\$ 1.943	1,035,752	D	

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	03/20/2015	S(1)	11,500	D	\$ 1.95	1,024,252	D	
Common Stock	03/20/2015	S <u>(1)</u>	2,100	D	\$ 1.96	1,022,152	D	
Common Stock						37	I	Trust for Children

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	5. ctionNumber of Securitie Acquire (A) or Dispose of (D) (Instr. 3 4, and 5	(Month/Day. ve es d d	Pate	7. Title Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code	V (A) (D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address			Relationships	
	Director	10% Owner	Officer	Other

BIANCO LOUIS A 3101 WESTERN AVE SUITE 600 SEATTLE, WA 98121

EVP, Finance & Administration

Signatures

Louis A. Bianco	03/20/2015
**Signature of	Date

Reporting Owners 2

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to a rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.